Many pharmaceutical products sold in the U.S. could have significant exposure to forced labor from their China-based supply chains, according to a report from risk management company Exiger.
The International Trade Commission published notices in the April 17 Federal Register on the following antidumping and countervailing duty (AD/CVD) injury, Section 337 patent or other trade proceedings (any notices that warrant a more detailed summary will be in another ITT article):
The Commerce Department published notices in the Federal Register April 17 on the following antidumping and countervailing duty (AD/CVD) proceedings (any notices that announce changes to AD/CVD rates, scope, affected firms or effective dates will be detailed in another ITT article):
The Consumer Product Safety Commission announced the following voluntary recalls April 17:
On April 16, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Foreign-Trade Zones Board issued the following notices April 17:
Forty-seven senators and representatives, led by Sen. Elizabeth Warren, D-Mass., expressed concern April 16 that the Trump administration’s reciprocal tariff policies negotiations could become a spoils system.
An April 15 executive order from President Donald Trump calls for examining the impact of importing higher volumes of prescription drugs to lower prescription drug costs in the U.S.
CBP issued the following releases on commercial trade and related matters:
A listing of recent Commerce Department antidumping and countervailing duty messages posted on CBP's website April 16, along with the case number(s) and CBP message number, is provided below. The messages are available by searching for the listed CBP message number at CBP's ADCVD Search page.